Parastoo Karimi Aliabadi1, Mehrnoush Sohrab1, Amirhossein Hessami2, Mahdi Afshari3, Zahra Kashi1, Motahareh Kheradmand4, Akbar Hedayatizadeh-Omran5, Reza Alizadeh-Navaei5, Mahmood Moosazadeh6. 1. Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 2. Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 3. Pediatric Gastroenterology and Hepatology Research Center, Zabol University of Medical Sciences, Zabol, Iran. 4. Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran. 5. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 6. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran. mmoosazadeh1351@gmail.com.
Abstract
BACKGROUND: The association between liver enzymes and metabolic syndrome (MetS) has been evaluated in several studies with different results. The purpose of this study is to determine the association between the serum levels of these liver enzymes and MetS in Tabari cohort population. METHOD: In this case-control study, data collected from the enrolment phase of the Tabari cohort population have been used. MetS was defined based on IDF (international diabetes federation) standards. Then, 476 patients with MetS (case group) and 476 age-sex matched controls were selected randomly. RESULTS: Mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher in case group than control group (20.59 vs. 19.99 respectively, p = 0.339 and 24.64 vs. 20.16 respectively, p < 0.001). The chance of having MetS, high triglyceride, and fasting blood glucose (FBG) was significantly higher in people with ALT ≥ 40 (1.63, 2.35, and 2.02, respectively). The chance of having MetS in people with AST ≥ 40 was 1.45 times higher than that among those with normal AST level (p > 0.05). CONCLUSION: This study showed that there is an association between liver enzymes and MetS as well as some of its components. Liver enzymes, especially ALT, can be used as an early indicator of MetS in the at risk population.
BACKGROUND: The association between liver enzymes and metabolic syndrome (MetS) has been evaluated in several studies with different results. The purpose of this study is to determine the association between the serum levels of these liver enzymes and MetS in Tabari cohort population. METHOD: In this case-control study, data collected from the enrolment phase of the Tabari cohort population have been used. MetS was defined based on IDF (international diabetes federation) standards. Then, 476 patients with MetS (case group) and 476 age-sex matched controls were selected randomly. RESULTS: Mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher in case group than control group (20.59 vs. 19.99 respectively, p = 0.339 and 24.64 vs. 20.16 respectively, p < 0.001). The chance of having MetS, high triglyceride, and fasting blood glucose (FBG) was significantly higher in people with ALT ≥ 40 (1.63, 2.35, and 2.02, respectively). The chance of having MetS in people with AST ≥ 40 was 1.45 times higher than that among those with normal AST level (p > 0.05). CONCLUSION: This study showed that there is an association between liver enzymes and MetS as well as some of its components. Liver enzymes, especially ALT, can be used as an early indicator of MetS in the at risk population.
Authors: Víctor Micó; Rodrigo San-Cristobal; Roberto Martín; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Montserrat Fitó; Ángel M Alonso-Gómez; Julia Wärnberg; Jesús Vioque; Dora Romaguera; José López-Miranda; Ramon Estruch; Francisco J Tinahones; José Lapetra; J Luís Serra-Majem; Aurora Bueno-Cavanillas; Josep A Tur; Vicente Martín Sánchez; Xavier Pintó; Miguel Delgado-Rodríguez; Pilar Matía-Martín; Josep Vidal; Clotilde Vázquez; Ana García-Arellano; Salvador Pertusa-Martinez; Alice Chaplin; Antonio Garcia-Rios; Carlos Muñoz Bravo; Helmut Schröder; Nancy Babio; Jose V Sorli; Jose I Gonzalez; Diego Martinez-Urbistondo; Estefania Toledo; Vanessa Bullón; Miguel Ruiz-Canela; María Puy- Portillo; Manuel Macías-González; Nuria Perez-Diaz-Del-Campo; Jesús García-Gavilán; Lidia Daimiel; J Alfredo Martínez Journal: Front Endocrinol (Lausanne) Date: 2022-09-06 Impact factor: 6.055